Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease.

Erdheim-Chester disease (ECD) is a rare non-Langherans form of histiocytosis characterized radiologically by symmetrical sclerosis of the metaphysis and the diaphysis of long tubular bones. Macrophages are potent interleukin-6 (IL-6) producers and elevated IL-6 serum levels have been described in pathological conditions characterized by increased bone resorption. In a patient with ECD, during the acute phase of the disease we found high serum levels of IL-6 and IL-6 soluble receptor (sIL-6R) andhigh levels of bone turnover markers. After 5 years of combination therapy with oral prednisone and intravenous clodronate a significant reduction in the above mentioned biological parameters was seen. We suggest that the systemic disorders presentin ECD could be related to the high serum levels of IL-6 and sIL-6R. We also propose the use of bisphosphonates in the clinical management of ECD.

作 者：

Mossetti G；Rendina D；Numis FG；Somma P；Postiglione L；Nunziata V

刊 名：

Clinical and experimental rheumatology 

年，卷(期)：

2003V.21(no.2) 

分类号：

 

关键词：

Antimetabolites  Bone Remodeling  Clodronic Acid  Diphosphonates  Erdheim-Chester Disease  抗代谢药  骨重建  氯屈膦酸  二膦酸盐类  白细胞介素6  受体, 白细胞介素6

正文语种：

eng 

基金项目：